Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
According to the World Cancer Research Fund International, ovarian cancer is the eighth most frequent malignancy in women worldwide. In 2022, there were around 324,603 new cases of ovarian cancer across the globe. The lifetime risk of ovarian cancer for a woman is approximately 1 in 87. A woman has roughly a 1 in 130 lifetime probability of passing away from ovarian cancer. With a mere 29% 5-year survival rate, most cases (85%) are identified with either distant or regional stage illness. Several companies are engaged in research initiatives which is boosting the drug landscape significantly.
- Major companies involved in the advanced ovarian cancer pipeline drugs market include AstraZeneca, F. Hoffmann-La Roche AG and Pfizer among others.
- Leading drugs currently under pipeline include Relacorilant, and Pamiparib among others.
- Regulatory authorities such as the United States FDA and EMA play a vital role in the drug pipeline for advanced ovarian cancer as they are offering breakthrough designations and fast-track approvals to several drugs, intended to provide effective treatment to patients having advanced ovarian cancer.
Report Coverage
The Advanced Ovarian Cancer Drug Pipeline Report by Expert Market Research gives comprehensive insights into advanced ovarian cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced ovarian cancer. The report includes the analysis of over 100 pipeline drugs and 25+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from advanced ovarian cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing product development activities related to advanced ovarian cancer are covered.
Advanced Ovarian Cancer Drug Pipeline Outlook
Advanced ovarian cancer is a condition in which malignant tumor cells migrate outside the ovaries to other parts of the body, resulting in life-threatening health issues. Although the exact cause of the disease is unknown, there are several risks associated with the disease. Some of the identified risk factors are postmenopausal women, advancing age, certain specific kinds of genetic mutations, late menopause, etc. Furthermore, obesity and endometriosis are also identified as crucial risk factors associated with the disease.
For the management and treatment of advanced ovarian cancer, a combination of chemotherapy, surgery and targeted therapy is used. Surgical interventions such as oophorectomy and hysterectomy are preferred in the initial stages to excise as much tumor mass as possible. Successful completion of the surgical procedure is followed by administering systemic chemotherapy agents such as paclitaxel and carboplatin for the expulsion of remaining cancer cells. Anti-angiogenic drugs and PARP inhibitors are examples of targeted therapy that may be used, especially in individuals who have certain genetic abnormalities.
Advanced Ovarian Cancer – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of liver fibrosis drugs based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Molecule Type
- Small Molecule
- Monoclonal Antibody
- Peptides
- Polymer
- Gene Therapy
By Route of Administration
- Oral
- Parenteral
- Others
Advanced Ovarian Cancer – Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total clinical trials for advanced ovarian cancer with 56 pipeline drugs in the respective phase.
Advanced Ovarian Cancer – Pipeline Assessment Segmentation, By Molecule Type
The drug molecules categories covered under advanced ovarian cancer pipeline analysis include small molecule, monoclonal antibody, peptide, polymer, and gene therapy. Several trials are ongoing to assess the efficacy of small molecules. Studies that targeted monoclonal antibodies have been highly effective in the management of advanced ovarian cancer. The report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for advanced ovarian cancer.
Advanced Ovarian Cancer Clinical Trials Assessment – Competitive Dynamics
The EMR report for the advanced ovarian cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in advanced ovarian cancer clinical trials:
- AstraZeneca plc
- Corcept Therapeutics Inc.
- Onconic Therapeutics Inc.
- F. Hoffmann-La Roche AG
- Merck Sharp & Dohme LLC
- Pfizer, Inc.
- ENB Therapeutics, Inc.
- Allarity Therapeutics Inc.
- Tesaro, Inc.
- Jazz Pharmaceuticals plc
- ImmunoGen, Inc.
Advanced Ovarian Cancer – Pipeline Drugs Profile
Major drugs currently in the drug pipeline are as follows:
Avastin
The trial evaluates the efficacy and safety of Avastin in patients with advanced ovarian cancer. The trial is sponsored by F. Hoffmann-La Roche AG and is currently under phase IV.
Avelumab
The study evaluates the safety of Avelumab for the treatment of advanced ovarian cancer. The trial is sponsore...
Olaparib
To assess the effectiveness of olaparib in patients with advanced ovarian cancer when combined with paclitaxel...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Reasons To Buy This Report
The Advanced Ovarian Cancer Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for advanced ovarian cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within advanced ovarian cancer pipeline insights.
Key Questions Answered in the Advanced Ovarian Cancer – Pipeline Assessment Report
- What is the current landscape of advanced ovarian cancer pipeline drugs?
- How many companies are developing advanced ovarian cancer drugs?
- How many phase III and phase IV drugs are currently present in advanced ovarian cancer pipeline drugs?
- Which companies/institutions are leading the advanced ovarian cancer drug development?
- What is the efficacy and safety profile of advanced ovarian cancer pipeline drugs?
- What are the opportunities and challenges present in the advanced ovarian cancer drug pipeline landscape?
- Which company is conducting major trials for advanced ovarian cancer drugs?
- What geographies are covered for advanced ovarian cancer clinical trials?
- What are emerging trends in advanced ovarian cancer clinical trials?
Related Reports
Global Psoriatic Arthritis Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Molecule Type |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Purchase Full Report
Datasheet
USD 1,999
tax inclusive*
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
USD 2,499
tax inclusive*
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
USD 3,499
tax inclusive*
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
USD 4,499
tax inclusive*
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124